Your browser doesn't support javascript.
Association Between Drug Treatments and the Incidence of Liver Injury in Hospitalized Patients With COVID-19.
Gao, Suyu; Yang, Qingqing; Wang, Xuanxuan; Hu, Wen; Lu, Yun; Yang, Kun; Jiang, Qiaoli; Li, Wenjing; Song, Haibo; Sun, Feng; Cheng, Hong.
  • Gao S; Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Yang Q; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
  • Wang X; Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Hu W; Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Lu Y; Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Yang K; Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Jiang Q; Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Li W; Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Song H; Key Laboratory for Research and Evaluation of Pharmacovigilance, National Medical Products Administration, Beijing, China.
  • Sun F; Chinese Society of Toxicology, Beijing, China.
  • Cheng H; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Front Pharmacol ; 13: 799338, 2022.
Article in English | MEDLINE | ID: covidwho-1779956
ABSTRACT
The outbreak of coronavirus disease 2019 (COVID-19) has led to the emergence of global health care. In this study, we aimed to explore the association between drug treatments and the incidence of drug-induced liver injury (DILI) in hospitalized patients with COVID-19. A retrospective study was conducted on 5113 COVID-19 patients in Hubei province, among which 395 incurred liver injury. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by Cox proportional hazards models. The results showed that COVID-19 patients who received antibiotics (HR 1.97, 95% CI 1.55-2.51, p < 0.001), antifungal agents (HR 3.10, 95% CI 1.93-4.99, p < 0.001) and corticosteroids (HR 2.31, 95% CI 1.80-2.96, p < 0.001) had a higher risk of DILI compared to non-users. Special attention was given to the use of parenteral nutrition (HR 1.82, 95% CI 1.31-2.52, p < 0.001) and enteral nutrition (HR 2.71, 95% CI 1.98-3.71, p < 0.001), which were the risk factors for liver injury. In conclusion, this study suggests that the development of DILI in hospitalized patients with COVID-19 needs to be closely monitored, and the above-mentioned drug treatments may contribute to the risk of DILI.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Journal: Front Pharmacol Year: 2022 Document Type: Article Affiliation country: Fphar.2022.799338

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Journal: Front Pharmacol Year: 2022 Document Type: Article Affiliation country: Fphar.2022.799338